Print PDF

Sheppard Mullin Represented US Pharma Lab in Successful Sale to Biofarma Group


Sheppard Mullin advised US Pharma Lab, a leading, fast-growing and innovative Contract Development and Manufacturing Organization (“CDMO”), in its acquisition by Biofarma Group, an Italian and European market leader in the development, manufacturing and packaging of dietary supplements. The acquisition was first announced in May 2023, and marks the first global CDMO focused on nutraceuticals.

The Sheppard Mullin deal team that represented US Pharma Lab was led by partner Ariel Yehezkel and included special counsel Amanda Ackerman, attorney Patrick Hao and associate Allison Troianos. Tax aspects of the transaction were led by partners Josh McLane and John Crisp, with invaluable assistance from many other specialists.

Click here to read the press release.

Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.